Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog
Ethambutol 400mg tablet/capsule											
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule											
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Isoniazid/Rifampicin 75/150mg tablet/capsule											
Isoniazid/Rifampicin 150/300mg tablet/capsule											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: August 2023







Status Yes No


N/A

Ineligible for inclusion



Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DS-TB: Drug-Susceptible TB EML: Essential Medicines List EOI: Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: August 2023







Yes



Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB ′17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifapentine 150mg tablet												
Rifapentine 300mg												
Rifapentine/Isoniazid 300mg/300mg tablet												-
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet												
Rifapentine/Isoniazid/Moxifloxacin/ Pyrazinamide 300/75/100/375mg tablet												-

DS-TB: Drug-Susceptible TB EML: Essential Medicines List EOI: Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: August 2023







